Controversial issues and new discoveries in lung neuroendocrine tumors

Diagnostic Histopathology

Volumn 20, Issue 10, 2014, Pages 392-397

  Pelosi, Giuseppe ^a,b   Hiroshima, Kenzo ^c   Mino Kenudson, Mari ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Tokyo Women s Medical University   (Japan)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinoid; Grading; Ki 67 antigen; Labeling index; LCNEC; Lung; Mitoses; Molecular; Necrosis; Neuroendocrine; Prognosis; SCLC

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; E1A ASSOCIATED P300 PROTEIN; EPHRIN RECEPTOR A7; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; SLIT2 PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX2; UBIQUITIN PROTEIN LIGASE COP1; VILLIN;

ATYPICAL CARCINOID NEUROENDOCRINE TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CARCINOID; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG TUMOR; NEUROENDOCRINE TUMOR; REVIEW; SMALL CELL LUNG CANCER; TUMOR DIFFERENTIATION; TYPICAL CARCINOID NEUROENDOCRINE TUMOR;

EID: 84908206335     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2014.09.007     Document Type: Review

References (40)

1. Travis W., Brambilla E., Muller-Hermelink H., Harris C. Tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
2. Swarts D.R., Claessen S.M., Jonkers Y.M., et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol 2011, 179:1129-1137.
3. Swarts D.R., Ramaekers F.C., Speel E.J. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012, 1826:255-271.
4. Pelosi G., Papotti M., Rindi G., Scarpa A. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 2014, 25:151-164.
5. Fernandez-Cuesta L., Peifer M., Lu X., et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 2014, 5:3518.
6. Iwakawa R., Takenaka M., Kohno T., et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer 2013, 52:802-816.
7. Peifer M., Fernandez-Cuesta L., Sos M.L., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1110.
8. Rudin C.M., Durinck S., Stawiski E.W., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44:1111-1116.
9. (NGM) TclcgpCangm Agenomics-based classification of human lung tumors. Sci Transl Med 2013, 5. 209ra153.
10. Moran C.A., Suster S., Coppola D., Wick M.R. Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 2009, 131:206-221.
11. Asamura H., Kameya T., Matsuno Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. JClin Oncol 2006, 24:70-76.
12. Rindi G., Klersy C., Inzani F., et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2014, 21:1-16.
13. Righi L., Volante M., Tavaglione V., et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 2010, 21:548-555.
14. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934-944.
15. Gridelli C., Rossi A., Airoma G., et al. Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev 2013, 39:466-472.
16. Travis W.D., Gal A.A., Colby T.V., Klimstra D.S., Falk R., Koss M.N. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998, 29:272-279.
17. den Bakker M.A., Willemsen S., Grunberg K., et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 2010, 56:356-363.
18. Ha S.Y., Han J., Kim W.S., Suh B.S., Roh M.S. Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis. Korean J Pathol 2012, 46:42-47.
19. Marchevsky A.M., Gal A.A., Shah S., Koss M.N. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001, 116:466-472.
20. Hiroshima K., Iyoda A., Shida T., et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006, 19:1358-1368.
21. Hiroshima K. Small cell carcinoma: distinction from large cell neuroendocrine carcinoma. Small cell carcinomas: causes diagnosis treat 2009, 101-121. Nova Science Publishers, New York. J.G. Maldonado, M.K. Cervantes (Eds.).
22. Bari M.F., Brown H., Nicholson A.G., et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. Histopathology 2014, 64:547-556.
23. Fernandez-Cuesta L., Peifer M., Lu X., et al. Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets (abstract #1531) 2014, AACR Annual Meeting of the American Association of Cancer Research, San Diego (CA).
24. Rea F., Callegaro D., Favaretto A., et al. Long term results of surgery and chemotherapy in small cell lung cancer. Eur J Cardiothorac Surg 1998, 14:398-402.
25. Nicholson S.A., Beasley M.B., Brambilla E., et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002, 26:1184-1197.
26. Jones M.H., Virtanen C., Honjoh D., et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004, 363:775-781.
27. Beasley M.B., Thunnissen F.B., Brambilla E., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000, 31:1255-1265.
28. Travis W.D., Linnoila R.I., Tsokos M.G., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-553.
29. Swarts D.R., van Suylen R.J., den Bakker M.A., et al. Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 2014, 38:1429-1436.
30. Axiotis C. The neuroendocrine lung. Endocrine pathology 2002, 261-296. Churchill Livingstone, New York Edinburgh. V. Li Volsi, S. Asa (Eds.).
31. Huang Q., Muzitansky A., Mark E.J. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med 2002, 126:545-553.
32. Pelosi G., Rindi G., Travis W.D., Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. JThorac Oncol 2014, 9:273-284.
33. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39:707-712.
34. Yang Z., Tang L.H., Klimstra D.S. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. Semin Diagn Pathol 2013, 30:186-196.
35. Cerilli L.A., Ritter J.H., Mills S.E., Wick M.R. Neuroendocrine neoplasms of the lung. Am J Clin Pathol 2001, 116(suppl):S65-S96.
36. Wick M.R. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 2000, 113:331-335.
37. Wegner M. SOX after SOX: SOXession regulates neurogenesis. Genes Dev 2011, 25:2423-2428.
38. Gontan C., de Munck A., Vermeij M., Grosveld F., Tibboel D., Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol 2008, 317:296-309.
39. Sholl L.M., Long K.B., Hornick J.L. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010, 18:55-61.
40. Marchetti A., Felicioni L., Pelosi G., et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 2008, 29:609-616.